Rizika dlouhodobé antisekreční terapie
| Title in English | Risk of long-term antisecretory treatment with proton pum inhibitors |
|---|---|
| Authors | |
| Year of publication | 2010 |
| Type | Article in Periodical |
| Magazine / Source | Vnitřní lékařství |
| MU Faculty or unit | |
| Citation | |
| Field | Other specializations of internal medicine |
| Keywords | proton pump inhibitors - antacids - gastroesophageal reflux disease - treatment - adverse events |
| Description | At present, pharmacoteraphy leading to a reduction in hydrochloric acid production in the stomach constitutes the core treatment strategy for the majority of the upper intestinal tract disease. Proton pump inhibitors (PPIs) are the predominant therapeutic group. Gastroesophageal reflux disease is the main indication for the long-term PPI use. Chronic use might be associated with adverse reactions. Potential risks take a form of malabsorption of certain food nutrients with their consequent deficiency, bacterial overgrowth and increased incidence of infections as well as altered regulation of proliferation of gastric as well other mucosas. Individual risk are low, their assessment is mostly based on the results of population studies. Even though the treatment benefits outweigh any potential theoretical risk, it is wise to decide well on the correct indication and to prescribe the lowest effective dose. |
| Related projects: |